ArticleMycotoxin research2025
On-farm evaluation of aflatoxin binder inclusion in dairy feed as a strategy to reduce milk aflatoxin M1 contamination in the Rwandan context.
Article in Mycotoxin research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Aflatoxins (AF), fungal metabolites, can contaminate feed in favorable environments, posing health risks to humans and animals. Dairy cows exposed to aflatoxin B1 (AFB1) excrete its metabolite, aflatoxin M1 (AFM1), in milk, compromising its safety. The current study examined the use of an AF binder in dairy feed concentrates on farms in Rwanda to mitigate AFM1 in milk. It was conducted in Nyagatare district, peri-urban areas of Kigali (Center), and Huye district (South) with 42 farmers randomly selected from a previous study evenly divided into control and intervention groups. The intervention group received an AF binder (Novasil™ Plus) and training on both the usage of the binder and AF prevention in dairy feed. Sociodemographic and dairy management data were collected through semi-structured questionnaires. Farmers in both the treatment and control groups were visited at regular intervals over a 3-month time period (five total visits per farmer) to collect samples of milk and feed for the quantification of AFM1 and AFB1, respectively, and to interview participants. The use of the AF binder evidenced a significant reduction in milk AFM1 contamination between the intervention (mean, 0.15 µg/l; median, 0.13 µg/l) and control groups (mean, 0.30 µg/l; median, 0.24 µg/l) (p < 0.05). AFB1 was detected in the feed concentrate at a mean concentration of 32.2 µg/kg (median, 36.2 µg/kg); however, mean AFM1 levels in both groups (i.e., control and intervention) did not exceed the Rwanda Standards Board (RSB) regulatory limit of 0.5 µg/kg AFM1. AF binders show potential as a low-cost strategy to reduce AFM1 contamination in the Rwandan context. However, there is a need for clear standards on the registration and use of binders before they are deployed in-country and to claim their mitigating effects on AFM1 in milk.
Indexed as
Identifiers
39666186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.